Sergey Ayzenberg, MD
Cardiovascular Disease · Brooklyn, NYNPI 1306031125
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,887 of the $156,936 with a category attached, or 68.1%. Amgen accounts for 60.8% of it on its own, with 34 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 727 payments — averaging $215.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$95K
- Shockwave Medical, Inc$21K
- Medtronic$20K
- Cook Medical LLC$3K
- Boston Scientific$2K
- Cook Incorporated$2K
- plus $13K from 29 others
Across 1 payment — averaging $8280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$8K
What the payments were for
- Consulting fees$9,9006%
- Speaking & faculty fees$106,88768%
- Travel & lodging$8,5215%
- Food & beverage$31,62820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 188 | $95,346 |
| Shockwave Medical, Inc | 45 | $21,407 |
| Medtronic(2 entities) | 130 | $20,452 |
| Cook Medical LLC | 54 | $2,644 |
| Boston Scientific | 21 | $2,118 |
| Cook Incorporated | 4 | $1,886 |
| Abiomed | 15 | $1,717 |
| Cardiovascular Systems Inc. | 21 | $1,587 |
| Asahi Intecc USA, Inc. | 7 | $1,489 |
| Philips North America LLC | 17 | $1,450 |
| Penumbra, Inc. | 6 | $1,079 |
| Pfizer | 43 | $927 |
| Abbott | 8 | $672 |
| Novartis | 34 | $637 |
| Bayer | 8 | $478 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $434 |
| AstraZeneca | 11 | $340 |
| Sanofi-aventis U.S. LLC | 14 | $318 |
| E.r. Squibb & Sons, L.L.C. | 19 | $265 |
| Merck | 11 | $250 |
| Alnylam Pharmaceuticals Inc. | 8 | $218 |
| Johnson & Johnson | 12 | $202 |
| Edwards Lifesciences | 1 | $196 |
| Stryker | 2 | $176 |
| Cagent Vascular Inc | 1 | $148 |
| Gilead | 5 | $93 |
| Chiesi USA, Inc. | 4 | $77 |
| Vifor Pharma, Inc. | 4 | $75 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $65 |
| Amarin Pharma, Inc. | 2 | $43 |
| Bridgebio Pharma, Inc. | 2 | $40 |
| Irhythm Technologies, Inc. | 2 | $39 |
| Boehringer Ingelheim | 1 | $33 |
| Heartflow, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$93,602
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$20,768
- SYMPLICITY G3$13,706
- RESOLUTE ONYX$1,532
- ONYX FRONTIER$1,505
- Impella$1,445
- Zilver Vena$1,403
- Diamondback Peripheral$1,285
- (6574) Coronary Other$1,004
- Indigo System$980
- SYNERGY$889
- Cook Medical Zilver PTX$841
- Zilver PTX$737
- Asahi Peripheral Vascular Wires$665
- Resolute$464
- AVVIGO Guidance System$457
- ASAHI PTCA Guide Wire$417
- PERIPHERAL VASCULAR$408
- Kerendia$385
- Zenith$366
How this compares
$156,936 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 396 | $306,396 |
| Repatha SureclickEvolocumab | 327 | $203,893 |
| EntrestoSacubitril/Valsartan | 110 | $84,099 |
| BrilintaTicagrelor | 144 | $83,380 |
| XareltoRivaroxaban | 31 | $32,473 |
| MultaqDronedarone Hcl | 28 | $26,071 |
| VascepaIcosapent Ethyl | 69 | $23,379 |
| MounjaroTirzepatide | 21 | $22,716 |
| Praluent PenAlirocumab | 35 | $19,601 |
| Diclofenac Sodium | 14 | $10,403 |
| Ranolazine ErRanolazine | 179 | $9,835 |
| JardianceEmpagliflozin | 12 | $9,359 |
| DapagliflozinDapagliflozin Propanediol | 18 | $9,147 |
| Icosapent Ethyl | 53 | $6,541 |
| TradjentaLinagliptin | 11 | $6,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $927 | $306,396396 claims |
| NovartisEntresto | $637 | $84,099110 claims |
| AstraZenecaBrilinta | $340 | $83,380144 claims |
| Johnson & JohnsonXarelto | $202 | $32,47331 claims |
| Sanofi-aventis U.S. LLCMultaq | $318 | $26,07128 claims |
| Boehringer IngelheimJardiance, Tradjenta, Pradaxa | $33 | $18,05136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$426K
- Warren WexelmanBrooklyn$396K
- Ozgen DoganBrooklyn$290K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.